Payer+Provider's Health System Review
FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering.
Potential consequences of patient complications for surgeon well-being: a systematic review.
April 17, 2019
Morgan L, Benson D, McCulloch P. BMJ. 2019;364:l1037.
Read the full post on AHRQ PSNet
